학술논문
A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
Document Type
Report
Author
Source
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. September, 2019, p1897, 15 p.
Subject
Language
English
ISSN
1178-7007
Abstract
Diabetes is a significant and independent risk factor for atherosclerotic cardiovascular disease (ASCVD), leading to morbidity and mortality among this population. The prevention of macrovascular complications, such as CVD, peripheral arterial disease, and cerebrovascular accident, in patients with diabetes is obtained through multifactorial risk reduction, including mixed dyslipidemia management and adequate glycemic control. For patients with diabetes, it is crucial to initiate adequate dyslipidemia therapy to achieve recommended low-density lipoprotein cholesterol (LDL-C) goal of
Introduction Over the last few decades, there has been a drastic increase in the prevalence of type 2 diabetes (T2D) within the United States, with numbers reaching over 30 million [...]
Introduction Over the last few decades, there has been a drastic increase in the prevalence of type 2 diabetes (T2D) within the United States, with numbers reaching over 30 million [...]